

1 JOHN J. SHAEFFER (SBN 138331)
jshaeffer@foxrothschild.com
2 Meeghan H. Tirtasaputra (SBN 325572)
mtirtasaputra@foxrothschild.com
3 FOX ROTHSCHILD LLP
10250 Constellation Boulevard, Suite 900
4 Los Angeles, California 90067
Telephone: 310-598-4150
5 Facsimile: 310-556-9828

6 Attorneys for Plaintiff
STARQUEST VENTURES, INC.

13 STARQUEST VENTURES INC. dba
14 Stelo, a California Corporation,

15 Plaintiff,

16 || v.

17 DEXCOM, INC., a Delaware Corporation;
18 and DOES 1-10, inclusive,

19 Defendants.

Case No.: 2:25-cv-05470-AH-JPR
Hon. Anne Hwang

**DECLARATION OF MEEGHAN H.
TIRTASAPUTRA IN SUPPORT OF
PLAINTIFF STARQUEST
VENTURES INC.'S MOTION FOR
PRELIMINARY INJUNCTION**

[Filed concurrently with Notice of Motion and Motion; Memorandum of Points and Authorities; Declarations of Paul Rample, Jessica Sheridan, and Kimberly B. Gatling; Compendium of Exhibits; Notice of Lodging; and [Proposed] Order]

Date: July 30, 2025
Time: 1:30 pm
Place: Courtroom 7D

Action Filed: June 16, 2025
Trial Date: None Set

1 **DECLARATION OF MEEGHAN H. TIRTASAPUTRA**

2 I, Meeghan H. Tirtasaputra, state and declare as follows:

3 1. I am an attorney duly licensed to practice law in the State of California
4 and admitted to practice in the Central District of California. I make this declaration
5 in support of Plaintiff StarQuest Ventures, Inc.'s Motion for Preliminary Injunction
6 in the above-captioned matter. I make this declaration of my own personal knowledge
7 and could and would so testify if called.

8 2. Attached as Exhibit 3 to the Compendium of Exhibits is a true and
9 correct copy of the 2024 Dexcom Annual Report.

10 3. Attached as Exhibit 4 to the Compendium of Exhibits is a true and
11 correct copy of the 510(k) Substantial Equivalence Determination Decision
12 Summary.

13 4. Attached as Exhibit 5 to the Compendium of Exhibits is a true and
14 correct copy of an FDA News Release dated March 5, 2024, FDA Clears First Over-
15 the-Counter Continuous Glucose Monitor.

16 5. Attached as Exhibit 6 to the Compendium of Exhibits is a true and
17 correct copy of US Trademark Application Serial No. 98274053 (STELO),
18 Application filed on November 16, 2023.

19 6. Attached as Exhibit 7 to the Compendium of Exhibits is a true and
20 correct copy of a news blogpost by DexCom, Inc. Investors News entitled, "Stelo by
21 Dexcom First Glucose Biosensor Cleared by FDA as Over-the-Counter", dated
22 March 5, 2024.

23 7. Attached as Exhibit 8 to the Compendium of Exhibits is a true and
24 correct copy of the Stelo User Guide Revised March 2025.

25 8. Attached as Exhibit 9 to the Compendium of Exhibits is a true and
26 correct copy of a screenshot of the Stelo by Dexcom App on Google Play.

27 ///

28

1 9. Attached as Exhibit 10 to the Compendium of Exhibits is a true and
2 correct copy of a screenshot of the homepage of Stelo.com as created by Dexcom.

3 10. Attached as Exhibit 11 to the Compendium of Exhibits is a true and
4 correct copy of a Time Magazine article entitled “The Best Inventions of 2024,”
5 featuring Dexcom’s Stelo Monitor.

6 11. Attached as Exhibit 12 to the Compendium of Exhibits is a true and
7 correct copy of an article from The Verge entitled “This over-the-counter gadget
8 could help the war against diabetes,” featuring Dexcom’s Stelo Monitor.

9 12. Attached as Exhibit 13 to the Compendium of Exhibits is a true and
10 correct copy of an article from The Verge entitled “Dexcom’s new continuous
11 glucose monitor is a health tech gadget with purpose,” featuring Dexcom’s Stelo
12 Monitor.

13 13. Attached as Exhibit 14 to the Compendium of Exhibits is a true and
14 correct copy of an article from the Journal of Multidisciplinary Healthcare, entitled
15 “Continuous Glucose Monitoring: A Transformative Approach to the Detection of
16 Prediabetes,” featuring Dexcom’s Stelo Monitor.

17 14. Attached as Exhibit 15 to the Compendium of Exhibits is a true and
18 correct copy of the first ten pages of a Google search of the term “Stelo.”

19 15. Attached as Exhibit 16 to the Compendium of Exhibits is a true and
20 correct copy of Dexcom’s Form 10-Q, Quarterly Report Ended March 31, 2025 filed
21 with the United States Securities and Exchange Commission.

22 16. Attached as Exhibit 17 to the Compendium of Exhibits is a true and
23 correct copy of a powerpoint presentation by Dexcom entitled “Dexcom’s Earnings
24 Q1 2025.”

25 ///

26 ///

27 ///

28

17. Attached as Exhibit 24 to the Compendium of Exhibits is a true and correct copy of Dexcom's Terms of Use at Stelo.com.

18. The USB drive being lodged with the Court contains the voice inquiries and files that were provided to my office by Jessica Sheridan.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct, and that this Declaration was executed on June 30, 2025 at Los Angeles, California

/s/ Meeghan H. Tirtasaputra
Meeghan H. Tirtasaputra